A PHASE Ia/Ib, OPEN LABEL, MULTICENTER, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7502175 AS A SINGLE AGENT AND IN COMBINATION WITH CHECKPOINT INHIBITOR IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Primary Objective
This is a first-in-human study to learn about the investigational drug called RO7502175.

Description
Participants will be enrolled in 2 stages: dose escalation and dose expansion.
Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator

Antonio Jimeno
Study ID
Protocol Number: 22-1245
More information available at ClinicalTrials.gov: NCT05581004
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers